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Abstract
Background: Atrial fibrillation (AF) has been recognised as an important independent risk factor
for thromboembolic disease, particularly stroke for which it provides a five-fold increase in risk.
This study aimed to determine the baseline prevalence and the incidence of AF based on a variety
of screening strategies and in doing so to evaluate the incremental cost-effectiveness of different
screening strategies, including targeted or whole population screening, compared with routine
clinical practice, for detection of AF in people aged 65 and over. The value of clinical assessment
and echocardiography as additional methods of risk stratification for thromboembolic disease in
patients with AF were also evaluated.
Methods: The study design was a multi-centre randomised controlled trial with a study population
of patients aged 65 and over from 50 General Practices in the West Midlands. These purposefully
selected general practices were randomly allocated to 25 intervention practices and 25 control
practices. GPs and practice nurses within the intervention practices received education on the
importance of AF detection and ECG interpretation. Patients in the intervention practices were
randomly allocated to systematic (n = 5000) or opportunistic screening (n = 5000). Prospective
identification of pre-existing risk factors for AF within the screened population enabled comparison
between high risk targeted screening and total population screening. AF detection rates in
systematically screened and opportunistically screened populations in the intervention practices
were compared to AF detection rate in 5,000 patients in the control practices.
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Atrial fibrillation (AF) has been recognised as an impor-
tant independent risk factor for thromboembolic disease,
particularly stroke with which it is associated with a five
fold increase in risk [1]. There are few data on the preva-
lence of AF in the United Kingdom. Local data derived
from the Echocardiographic Heart of England Screening
(ECHOES) study suggested a prevalence of AF in people
over the age of 65 of 3.8% (95% CI: 2.5–5.1) [2]. A review
of four large community based studies of AF suggested
that the overall community prevalence in the United
States is 0.89% [3]. In these studies, the prevalence
increased sharply with age: 2.3% of people aged 40 or
over; 5.9% of people aged over 65 (higher than the local
estimate), and 10% of those over 80. The vast majority
(84%) of people with AF are over the age of 65. AF is a par-
ticularly important risk factor for stroke in the elderly –
while 15% of all strokes are associated with the arrhyth-
mia, it is associated with 36% of strokes in people over the
age of 80. The incidence of new cases of AF in people over
the age of 65 is of the order of 1% per annum [4].
Screening for AF in the elderly fulfils many of the Wilson-
Jungner criteria for a screening programme [5]. It is a com-
mon and important condition which can be diagnosed by
means of a simple test, and the risk of serious sequelae
such as stroke can be dramatically reduced by treatment.
One UK study has compared systematic nurse-led screen-
ing with prompted opportunistic case finding for AF in
primary care [6]. This small scale study (four practices, n
= 3001) demonstrated that systematic nurse-led screening
detected more cases than opportunistic case finding, how-
ever most of those cases detected were already diagnosed.
Two further single practice based studies have investigated
the role of practice nurses in the screening process [7], and
whole population screening [8]. 5% of total NHS expend-
iture can be attributed to stroke, and there would be
expected to be about 1,000 new cases of stroke per annum
in a typical health authority of a half million population.
Therefore, any programme that might lead to an impor-
tant reduction in stroke incidence needs serious consider-
ation, both because of the potential for health gain, and
the potential for reduced overall NHS expenditure.
Screening for AF might be one such programme since, in
population terms, AF is an important risk factor for stroke
and anticoagulation provides a highly effective treatment
to reduce this risk. A meta-analysis of randomised control-
led trials has shown a 68% relative risk reduction in
patients' with AF receiving oral anticoagulation [9]. It has
been estimated that optimal treatment of AF in the popu-
lation might reduce the overall incidence of stroke by
10%. However, before implementing screening pro-
grammes, unresolved questions over how the screening
should be conducted must be answered.
The appropriate screening strategy to be employed
Opportunistic screening
The simplest strategy was opportunistic case finding, where
a health care professional took the opportunity to feel a
patient's pulse during a consultation. If the pulse is irreg-
ular, they might make a clinical diagnosis of AF, or
request/perform an electrocardiogram (ECG) as a con-
firmatory test. However, opportunistic case finding is
likely to miss a significant proportion of people who
would otherwise have benefited from treatment. For
example, detection of hypertension in general practice
was traditionally detected in an opportunistic way until
the introduction of health checks with the 1990 GP con-
tract. The Health Survey for England shows that in 1991,
42% of the population over the age of 75 had hyperten-
sion for which they were not taking any medication [10].
This figure had fallen to 31% by 1994, after the GP con-
tract had taken effect.
Targeted screening
One possible approach was to screen patients who are at
higher risk of AF – a targeted screening programme. Cardiac
failure, hypertension and rheumatic heart disease are
important precursors of AF [7]. AF is more common in
people with a history of myocardial infarction, angina,
diabetes mellitus, hyperthyroidism, stroke or transient
ischaemic attack (than in people without these condi-
tions) [11]. Most general practices were computerised,
and some have disease registers. A targeted screening pro-
gramme could exploit these to identify such high risk
patients, either through disease registers, or through pre-
scribing information on the computerised records.
Whole population screening
Another approach was to screen everyone 65 and over
(65+) for AF – a whole population screening programme.
A modelling exercise using decision analysis to inform on
the methodology for this study indicated that there were
not sufficient primary data available to recommend which
of these (targeted or whole population) would be the
optimum policy
The most appropriate screening test for AF
12-lead ECG is recognised as the gold standard test, but
this test is time consuming (taking at least 15 minutes to
perform in an outpatient setting). Therefore, it is impor-
tant to consider simpler tests. This study assessed simpler
methods compared to the gold standard, both in terms of
accuracy, time taken and patient acceptability. These
include taking the pulse, and simpler ECGs.
Interpreting the ECG
Cardiologists offer the most accurate readings of ECGs,
but can satisfactory interpretations be obtained by the GP,Page 2 of 11
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This study assessed the accuracy of these different
approaches to interpreting the ECG.
The value of echocardiography
The main treatment options to reduce risk of stroke in
patients' with AF are currently warfarin or aspirin. Aspirin
is much less effective than warfarin – it achieves a barely
significant 21% reduction in stroke risk [9]. However, it is
safer to use, since it confers a lower risk of serious haem-
orrhage. Therefore, in practice, the clinical decision as to
which treatment to use depends upon the balance of risks
and benefits for the individual patient. Thromboembolic
risk is currently determined primarily on clinical criteria.
Data from the SPAF study [12] suggested that echocardi-
ography (Echo) may inform on risk stratification, assist-
ing in therapeutic decision making. The role of routine
Echo for patients with AF identified in the community
remains to be proven. Data also needs to be quantified
regarding the cost effectiveness of Echo versus clinical
impression alone. Studies have suggested that the clinical
utility in people aged over 74 is poor [13,14]. Therefore
this study focused on patients aged 65–74. Once some-
body has been identified as having AF, should they also
receive an echocardiogram to assess their risk of stroke, or
is clinical assessment of risk adequate?
Optimum strategy
This study, by providing answers to these questions,
allowed the optimum strategy for introducing a screening
programme for AF in the over 65s to be determined. How-
ever, before a decision is made as to whether to institute a
screening programme, not only must the question of the
best strategy be considered, but also, the question of
whether any screening programme at all should be intro-
duced. This study provided data to assist in answering this
fundamental question by providing:
i) An accurate estimate of the community prevalence and
incidence of AF in over 65s;
ii) An assessment of the health economic implications of
screening for AF;
iii) An assessment of the service provision implications of
implementing such a programme;
iv) An assessment of the impact on patient quality of life
and anxiety after various screening methodologies.
Health economics of screening
Although the cost effectiveness of different approaches to
screening is often put in terms of the average cost per case
detected, such an approach ignores the sensitivity and spe-
cificity of the screening test. This is because average cost
per case detected focuses entirely on true positives, paying
no attention to false positives, false negatives and true
negatives. False positives and false negatives impose costs
on patients and health services which would be neglected
if the focus was confined to true positives [15]. An undue
emphasis on the average cost per case detected could jus-
tify opportunistic screening of a small number of high risk
patients who present, with no consideration of the
number of cases missed.
This study compared the incremental cost per case
detected for different methods of AF screening. This refers
not to the average cost but rather approximates the incre-
mental cost per case detected in moving from one of the
screening options to another. Use of incremental cost per
case detected by option shows how the cost per additional
case detected is likely to increase as the intensity of screen-
ing increases. This method has been used to deal with sim-
ilar uncertainties about the cost effectiveness of screening
for other diseases, including breast and colorectal cancer
and has been recommended by the US guidelines [16].
Objectives
Primary objective
• To determine baseline prevalence and the incidence of
AF based on a variety of screening strategies and in doing
so to evaluate the incremental cost-effectiveness, in terms
of cost per case identified, of the different screening strat-
egies (targeted or whole population screening) compared
with routine clinical practice for detection of AF in people
aged 65 and over.
Secondary objectives
• To evaluate the relative cost-effectiveness of screening
methods for AF diagnosis, comparing 12 lead ECG (gold
standard) with pulse taking, lead II rhythm strip from
standard ECG limb leads alone and single lead thoracic
placement ECG.
• To evaluate the most cost-effective method of test inter-
pretation, comparing cardiologist (gold standard), with
GP, practice nurse, or computerised diagnostic software.
• To assess the differing combinations of screening strate-
gies and procedures in terms of patient acceptability and
impact on patient quality of life, including any psycholog-
ical effects of screening.
• To determine the community prevalence of AF in people
65+.
• To evaluate the value of clinical assessment and echocar-
diography as additional methods of risk stratification for
thromboembolic disease in patients with AF.Page 3 of 11
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screening for AF become a national programme, and iden-
tify the optimum screening algorithm for identification of
patients with AF.
Outcome measures
Primary outcome
• The incidence of AF according to a variety of screening
strategies
• The associated costs providing an incremental cost per
case detected. The cost data was collected from an NHS
and patient perspective. It has focused on resources
required to establish screening, time taken to complete
screening and the cost of the equipment.
Secondary outcomes
• Cost effectiveness of 4 different methods of screening for
AF. The cost data focused on the difference in the cost of
the equipment and the time taken for each of the different
methods of screening to be completed. This was from
both an NHS and patient perspective.
• Cost effectiveness of 4 different methods of ECG inter-
pretation. The cost data focused on the difference in the
cost of the grade of staff interpreting the ECG and the
accuracy of their interpretation.
• Overall community prevalence and incidence of AF
• Patient acceptability to AF screening was measured using
an adapted version of the screening specific questionnaire
used in the Colorectal Screening Programme [18]. Patient
uptake of screening was also monitored. The impact on
quality of life was assessed using EQ-5D [24,25]. Patient
anxiety was measured using the Spielberger 6 item Anxiety
Questionnaire [17].
• Modelling techniques were used to identify the implica-
tions of AF screening on health service provision nation-
ally. This included the effect on echocardiography and
anti-coagulation clinic provision.
Methods
This was a multi-centre randomised controlled trial. The
study schema is shown in figure 1.
50 computerised general practices within the West Mid-
lands were recruited through MidReC (Midlands Research
Practices Consortium). This was undertaken by writing to
all practices in the West Midlands and surrounding coun-
ties explaining the study and asking whether they were
interested in participating. Practices showing an interest
were given further information about the study and
invited to attend an investigators meeting. Following the
investigator meetings sixty practices interested in partici-
pating in the project were randomised (stratified based on
Townsend score and practice list size): 25 as intervention,
25 as control practices with 10 reserve practices.
A computerised list of all patients aged 65+ was obtained
from each practice, and from this a random sample of
10,000 patients from the intervention practices (repre-
senting approximately 1/3rd of the total population of
patients 65+ in this group), and 5000 from the control
practices (representing approx. 1/6th of the total popula-
tion of patients 65+ in this group) were identified.
Patients from intervention practices were randomised, by
patient, to opportunistic or systematic groups. All patients
within the systematic screening arm, including those with
a history of AF, were invited by post to attend a screening
clinic.
For patients in the opportunistic arm, their notes were
flagged within the practice to encourage practice staff to
undertake pulse recording. Patients with an irregular pulse
were invited to attend a screening clinic. Once this process
had been undertaken, the flag was removed from the
notes and returned to the research team.
The screening clinic was run by practice nurses. Patients
gave informed consent. Data collected was baseline infor-
mation, past medical history (including any previous
diagnosis of AF), radial pulse and a 12 lead ECG. The 12
lead ECG was performed using an electronic ECG
machine which allowed print-out of single lead thoracic
placement ECG and a rhythm strip of lead 2 using limb
leads from standard ECG.
All 12 lead ECGs were sent to two cardiologists for report-
ing (GL, MD). Where there was disagreement over the
diagnosis a third cardiologist was used to decide. The car-
diologists were asked to state whether the ECG showed AF
or not, and to state whether there were any other signifi-
cant abnormalities. Patients were informed of the result
within two weeks. Patients with normal ECGs were
informed of this, patients with any abnormality were
asked to make an appointment with their GP. At the GP
appointment patients with AF aged 65 – 74 were offered
echocardiography. GPs were asked to make a clinical deci-
sion as to thromboprophylaxis both before and after the
echocardiogram. Patients with other ECG abnormalities
were managed as clinically indicated.
At the end of the screening process, GPs and Practice
Nurses from both intervention practices (who had
received education on ECG interpretation) and control
practices (who had received no education) were sent
ECGs to interpret for the presence or absence of AF. AllPage 4 of 11
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12 lead, single lead thoracic placement or limb lead
recordings. Allocation to ECG type was random and
resulted in three equal ECG groups. In order for each
interpreter to read all three types of ECG, batches of ECGs
were collated with the same numbers of each type of ECG.
Allocation to a batch was also random. In total, there were
25 batches of ECGs to match the number of practices in
each arm. The GP and Practice Nurse from the same prac-
tice read the same batch of ECGs and each batch was read
by one control practice and one intervention practice.
Therefore each ECG was read by two GPs and two Practice
Nurses. All ECGs were anonymised, and practices did not
receive any ECGs from their own practice. The interpreters
were given a sheet to fill in to indicate for each ECG the
presence or absence of AF. All ECGs (as 12 lead) were also
Study schema for the multi-centre randomised controlled trialFigure 1
Study schema for the multi-centre randomised controlled trial.
Patient Randomisation
350,000 Patients 
(50 Practices) 
All patients invited to attend 
screening clinic 
Systematic Screening
5,000 
Identify patients with a high risk of AF 
Patient Randomisation based at practice 
level and on presence of AF
Identify patients with known AF (A1)
Computer search for probable AF 
review case notes of all ‘+ves’ and 5% ‘-ves’ 
5,000 
random sample 
10,000 
random sample 
Control
30,000 
(25 practices)
Intervention
30,000 
(25 practices)
60,000  aged 65+ 
Identify patients with known AF (C1)
Computer search for probable AF 
review case notes of all ‘+ves’ and 5% ‘-ves’ 
Opportunistic Screening
5,000 
Tag all notes
If irregular pulse on routine clinic 
presentation invited for ECG
Identify patients with 
known AF- high risk 
(A2)
Computer search for probable AF
review case notes of all '+ves'  
Identify patients with 
known AF- all 
(A3)
Computer search for probable AF
review case notes of all '+ves'  
Identify patients with 
known AF 
(B2)
Computer search for probable AF
review case notes of all '+ves'  
Identify patients with 
known AF 
(C2)
Computer search for probable AF
review case notes of all '+ves'  
Practice RandomisationPage 5 of 11
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the electronic ECG and results recorded.
Patient acceptability and quality of life for different
screening strategies were established using EuroQol (EQ-
5D) combined together with the Speilberger 6-item Anxi-
ety Questionnaire. EQ-5D allowed the measurement of
broad aspects of quality of life. The shortened Speilberger
anxiety questionnaire also has proven validity and is more
specific to anxiety than is the SF-12 [17]. An adapted ver-
sion of the screening-specific tool used in the Colorectal
Screening Programme [18] was used to assess the accepta-
bility of the screening process.
A random sample of 750 patients (375 screened patients
and 375 opportunistically screened patients) were sent
postal versions of the psychological instruments (EQ-5D
and Spielberger) on entry to the study (i.e. before the
intervention group has received their invitation to attend
for screening). One reminder was sent a month later to
non-responders. The same questionnaires were sent to the
same groups plus those patients who had screened postive
at the end of the screening period, approximately 17
months later. This allowed a non-randomised compari-
son between the effects on quality of life and anxiety in
screen positive and screen negative patients.
In addition, all patients who were screened were asked to
complete the acceptability and Spielberger questionnaire
immediately after screening. The patient acceptability
questionnaire was also administered to all patients who
proceeded for echo.
The value of clinical assessment and echocardiography in
risk stratification were determined in patients aged 65–74.
This compared GP assessment based on the Birmingham
guidelines for thromboprophylaxis in AF with any
changes in recommendations for treatment once echocar-
diography results were available to the GP.
Sample size and power calculations
The assumptions for the power calculations were that
patients aged 65 and over represent 17% of the total pop-
ulation; that 40% of study population will be in the high
risk group.
Also assuming that:
1. Minimum worthwhile change in detection rate was 1%
for targeted screening versus routine practice. It is esti-
mated that this change would equate to £10,000 per life
year gained. This is based on the following assumptions:
a) 60% of new cases of identified AF would be suitable
candidates for warfarin
b) Annual risk of stroke in this population was 5%,
reduced by 60% to 2% if treated
c) Costs: £25 to screen a patient; £100 to treat with warfa-
rin pa; £6,000 NHS costs to treat a stroke
2. 50% of patients with AF will be already known to their
general practitioner (estimates range from 30% [19] to
76% [20])
3. Community prevalence of AF in this population was
6% [2]
See figure 1. It was assumed that the baseline prevalence
of AF known to the practice (A1) would be 3% (i.e. half of
real prevalence of 6%) and that the prevalence of known
AF in the control practices would remain constant over
the screening period. Thus, the change in the prevalence
of known AF in the control practices between baseline to
follow up (C2-C1) should be approximately 0%. The
change in the GP educated arm (B2-A1) should be mar-
ginally higher and is assumed to be between 0 and 1%.
The change in the systematic screening arm should, on
average, be between 0 and 3% and was assumed to be
approximately 2% for the total screening arm (A3-A1)
and in the high risk arm (A2-A1) was approximately 3%.
All sample size calculations were for 90% power and 5%
significance levels unless otherwise stated.
a) To detect a 1% difference in detection rate between interven-
tion (GP educated) and control practices (B2-A1) vs (C2-C1).
This requires 1,236 patients. However, since this is a dif-
ference based at the practice level of randomisation, it
needed to be inflated by the design factor. Based on AF
prevalence data from the EcHoES (Echocardiographic
Heart of England Screening) Study [2], the between prac-
tice variance is 3.7 and the within practice variance is 246.
This gave an intra-cluster correlation coefficient of 0.015.
The most efficient design in this circumstance would be a
cluster size of 200, which gives a design factor of 4. There-
fore, 5,000 patients would be needed in 25 practices in
both intervention (GP educated) and control groups.
b) To detect a 1% difference in detection rate between interven-
tion (Systematic screening total arm) and control practices
(A3-A1) vs (C2-C1). This requires 1,236 patients but when
scaled by the design factor of 4 required 5,000 patients.
c) To detect a 1.8% difference in detection rate between inter-
vention (Systematic screening high risk  arm) and control
practices (A2-A1) vs (C2-C1). This requires 684 patients.
However, since this is a difference based at the practice
level of randomisation, it also needed to be inflated by the
design factor. This meant that 2,736 patients would bePage 6 of 11
(page number not for citation purposes)
BMC Cardiovascular Disorders 2004, 4:12 http://www.biomedcentral.com/1471-2261/4/12needed in each arm. Since the ratio of patients in the two
arms is 2:5 this means that 1,916 patients would be
needed in the high risk arm and 4,789 in the control arm.
With the 2,000 patients expected to be at high risk in this
arm – resulting from the 5,000 needed for the previous
comparison there were more than enough patients to
detect the required difference.
Although comparison b) required fewer patients to detect
the expected difference (2%) stated in the assumptions, it
would be possible to detect differences as low as 1%,
should the detection rate not be as high as expected.
The a), b) and c) comparisons are all at practice level
randomisation.
d) To detect a 1% difference in detection rate between high risk
screening strategy and routine practice prompted by education
(opportunistic arm) (A2-A1) vs (B2-A1).This requires 1,236
patients in both the high risk systematic screening and the
GP educated (opportunistic) screening arms of the inter-
vention practices assuming the high risk screening detects
a 1% increase and opportunistic screening detects 0%
increase. Should the increased detection rates be higher in
each arm (1.7% in the high risk arm and 0.7% in the
opportunistic arm) then this could require 2,686 patients
in each arm. However, since there is a ratio of 2:5 patients
in these arms there will be sufficient patients as only 1,880
are needed in the high risk arm and 4,700 in the oppor-
tunistic arm to be able to detect this 1% difference.
e) To detect a 1% difference in detection rate between total
screening strategy and routine practice prompted by education
(opportunistic arm) (A3-A1) vs (B2-A1).This requires 3,300
patients in both the total screening and the GP educated
(opportunistic) screening arms of the intervention practices.
f) To detect a relative risk (RR) of 2 (1% detection rate differ-
ence) between total population and high risk screening (A3 vs
A2).It was assumed that 40% of the study population fall
into the high risk group, and the prevalence of undetected
AF is 3%. This meant that 1,434 patients would be needed
in each of the two risk groups to detect a two fold differ-
ence in risk (i.e. RR of AF in high risk as compared to low
risk group is 2). This RR of 2 equates to an increase in AF
detection rate from 3% in the total population arm to 4%
in the high risk arm. Since there was a 40:60 split in the
two risk groups unequal sample size calculations only
require a minimum of 1,200 patients in the high risk
group and 1,800 in the moderate/low risk group. This was
achievable with a screening arm of 5,000 patients, as there
would actually be 1,320 in the high risk group and 1,980
in the moderate risk group if a 66% screening acceptance
rate was assumed.
Sample size for quality of life assessment
Although some of the variances are from North American
populations we have no reason to suspect that the varia-
tion will be different in a British population since data
from the ECHOES study on the SF36 gives variations very
similar to the North American norms.
Spielberger
The shortened (6-item) version of the Spielberger state
anxiety questionnaire has been validated and used in pop-
ulations different from that under consideration in SAFE,
namely it tends to have been used in young and mostly
female populations [17,21,22]. The variance obtained
from these papers appears to be approximately 144 for
Marteau [17] but higher for the Ubhi [22] paper. How-
ever, the women in the latter paper were being informed
of major illness outcomes (either benign or malignant
breast cancer). A full Spielberger on people undergoing
physiological tests also gave a variance of the order of 144
[23]. The full version of the Spielberger state anxiety when
used with an elderly population also seems to give a vari-
ance that is not too far from the previously mentioned
papers being 188.8 [23]. Taking this latter value as being
the nearest to our population we can detect a 4 point dif-
ference in the mean values obtained with 249 patients in
each arm.
EQ5D
The VAS scale
The VAS variance as reported for an elderly population
aged 75 and over was 365 [24] but for a group of recov-
ered stroke patients (ages not given) it was approximately
100 [25]. Taking the former value as a worst case this
means it will be possible to detect a 6% difference
between groups on the VAS with 213 patients within each
group.
The Utility index
This was reported in different ways in the Johnson [24]
and Dorman [25] papers. Using the utility values from the
Dorman et al paper the variance is approximately 0.066
and this allows us to detect a 0.1 difference with 139.
Using the Johnson paper the variance is approximately
576 and using this means that we can detect a mean
change of 7 with 247 patients in each arm.
Statistical analysis
Intention to treat analysis will be used.
Any previously known Atrial Fibrillation cases will be sub-
tracted from the totals obtained at the end of the study to
ensure there is no double counting in the incidence
figures.Page 7 of 11
(page number not for citation purposes)
BMC Cardiovascular Disorders 2004, 4:12 http://www.biomedcentral.com/1471-2261/4/12Chi-squared, independent t-tests and log-linear models
will be used to describe demographic data. If there are dif-
ferences between the groups this may need to be adjusted
for in later analyses.
Primary objective: to determine baseline prevalence and 
incidence of AF on a variety of screening strategies
Proportions and rates will be used as the measures of prev-
alence and incidence.
The independent t-test and ANOVA with random effects
(as appropriate) will be used to examine the detection rate
differences between the intervention and control screen-
ing strategies. Should the data be strongly non-normal a
non-parametric equivalent will be used.
Secondary objectives
a) to assess patient acceptability and impact on QoL of different
screening strategies
The independent and related t-test and ANOVA will be
used to examine the differences between the intervention
screening strategies on the Spielberger and EuroQol
EQ5D. Should the data be strongly non-normal a non-
parametric equivalent will be used. Chi squared tests will
be used on the screening tool.
b) to assess the value of echocardiography in risk stratification
for thromboembolic disease in patients with AF
McNemar's test will be used to see whether there is any
significant change in the doctor opinion on risk of CVA
and treatment decision before and after echo screening.
c) to evaluate the most cost effective method of test
interpretation
The cost effectiveness will be covered in the economic sec-
tion. However, the use of sensitivity, specificity, Cohen's κ
and conditional logistic modelling will allow for compar-
ison of the various methods for detecting AF between the
GPs, nurses and consultants.
d) to evaluate the most cost effective method of screening
This will be covered in the economic analysis section.
Multivariate and logistic modelling analyses will be
undertaken in order to determine which markers might be
the best predictors of the presence of AF. This will act as
confirmatory analysis for the risk factors used in the
screening strategy to define a high risk patient.
Economic analysis
Framework for the economic analysis
This trial evaluated a large number of alternative screening
scenarios for identifying atrial fibrillation (2 screening
strategies i.e. target v population; 6 screening methods i.e.
pulse plus 3 types of ECG if pulse abnormal, and 3 types
of ECG regardless of pulse; and 4 screening test interpreta-
tions, making 2*6*4 = 48 plus control and opportunistic
screening = 50). The study has been powered to detect a
difference in the targeted versus population arms, and in
systematic screening versus routine clinical practice. How-
ever, the economic analysis will compare the cost-effec-
tiveness of all alternative screening approaches using a
modelling framework, whereby data will be drawn from
the trial (where appropriate and available) and from
external sources.
The use of a modelling approach allows the timescale for
the economic analysis to be extended beyond the follow-
up period allowed for in the trial. The use of such extrap-
olation will enable estimation of the incremental cost-
effectiveness ratios (ICERs) for each approach:
Incremental cost per case detected
Incremental cost per life year gained
Incremental cost per quality-adjusted life year (QALY)
gained
Data on consequences
The use of EQ-5D allows the measurement of broad
aspects of quality of life. EQ-5D allows changes in health
status to be measured but also valued, using the Univer-
sity of York Measurement & Valuation of Health general
population survey tariff [27].
Cost data
The cost analysis adopted a broad perspective to include
costs incurred within the health sector and by patients and
carers. Data collection was undertaken on all trial patients
in order to allow a stochastic cost analysis to be con-
ducted. The focus of the data collection will be upon the
key cost drivers which will include:
a) the resources required to establish screening (invitation
to patient, follow ups, communication of results),
b) the time taken to carry out the various tests, and
c) the cost of the equipment (expressed as cost per test).
a), b) and c) will be based on data collected in the study.Page 8 of 11
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data collection concentrated on resource use differences
between alternative screening scenarios. The process of
collecting data on resource use was undertaken separately
from data collection on unit costs. Resource use data on
the screening process was principally collected within the
trial. Unit costs were collected from published sources and
a representative sample of NHS providers in order to
increase generalisability. The methods used in collecting
data will include patient questionnaires (see above) and
review of patient records (both GP and hospital). Data on
private costs were collected from a survey of a sub-cohort
of the trial population.
Cost effectiveness analysis
The plan for the analysis is:
1. Report a cost consequence analysis, which will involve
providing a full description of all important results relat-
ing to costs and consequences.
2. Conduct both a cost-effectiveness analysis and a cost
utility analysis (using data on true positive cases detected
as the measure of effect and data on EQ-5D to estimate
QALYs).
An incremental approach will be used in order to compare
the large number of alternative screening strategies.
We are interested in comparing the mean costs per patient
since our concern is with predicting overall programme
costs. However, the data on costs are likely to have a
skewed distribution. Therefore, the plan for the analysis of
costs is:
1. To explore the nature of the distribution of costs
2. If required, to use non-parametric comparison of
means (e.g. bootstrapping)
3. If the distribution of the data is approximately normal,
parametric methods will be used.
This approach is in line with recent recommendations
[26].
If missing data are a problem at the economic analysis
stage, then imputation techniques will be employed.
Longer term costs and consequences will be explored by
extrapolating beyond the end of the trial using a model-
ling framework using data from a range of trial and non-
trial sources. The precise form of modelling is yet to be
determined, but is likely to be either Markov or Discrete
Event Simulation, depending upon the extent to which
the Markov assumptions are justified. An advantage of
using such an approach is that it will allow the additional
costs of increasing survival to be explicitly incorporated
into the analysis. In particular, modelling will provide
estimates of the optimal frequency of screening for AF,
based on the estimates of incidence and prevalence from
the trial.
Identifying untreated patients with AF will have implica-
tions for service provision. These will depend upon the
prevalence of atrial fibrillation, the screening mechanism
employed, the use made of echocardiography, and the
additional requirements for anticoagulation monitoring.
The separate parallel study, BAFTA, will provide empirical
data that will allow such implications for service provi-
sion to be assessed. The modelling exercise, which will
draw on both SAFE and later BAFTA results, will combine
best estimates of both screening and anticoagulation
options.
The robustness of the results of the economic analysis will
be explored using sensitivity analysis [27]. This will
explore uncertainties in the trial based data itself, the
methods employed to analyse the data and the generalis-
ability of the results to other settings. Uncertainty in the
confidence to be placed on the results of the economic
analysis will be explored by estimating cost-effectiveness
acceptability curves. These plot the probability that the
intervention is cost-effective against threshold values for
cost-effectiveness.
Inclusion and exclusion criteria
Inclusion criteria
Patients aged 65 years or over (65+).
Exclusion criteria
Patients who were terminally ill.
Randomisation
Randomisation of practices and patients was performed
by statisticians from the Department of Primary Care and
General Practice at The University of Birmingham. Cluster
randomisation of practices to intervention or control was
stratified by Townsend quartiles and practice size. Com-
puter searches were carried out to identify cases of known
AF, within the sample of patients identified above, using
a published strategy [15]. The randomisation of patients
within the intervention practices ensured that the study
patients in each practice were divided equally between
systematic and opportunistic screening arms and also that
there was an even distribution of patients with known AF
between the two arms. Patients within the systematic
screening arm were identified by computerised record
searching as either being at high risk (target population)Page 9 of 11
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nised criteria [28,11].
Cleaning of lists post randomisation
Following initial sampling of the total population the list
of patients from each practice were returned to the prac-
tices who were asked to remove any patients who had
died, moved or were terminally ill. Patients removed fol-
lowing this process were replaced with patients from a
reserve list, which had been randomised at the same time
as those on the initial lists.
Patient information and consent
Patients aged 65+ who were selected to the systematic
screening arm received an information sheet with an invi-
tation letter to attend the ECG clinic. Entry to the trial was
discussed with the practice nurse at the clinic. The practice
nurse then obtained written consent from those patients
who were willing to participate.
Study patients found opportunistically to have an irregu-
lar pulse were given an information sheet and invited to
attend the screening clinic.
Practice staff education and ECG training
GPs and other members of the primary health care team
in the intervention practices attended investigator days at
which they were given educational materials informing
them of the importance of detection of AF, and the treat-
ment options that are available. The materials encouraged
them to consider opportunistic screening of patients.
Members of the primary health care team in control prac-
tices received no educational input from the research staff.
Practice nurses attended an ECG training day prior to
starting the ECG screening clinics. Training included how
to perform an ECG (using the Biolog) to ensure a stand-
ardised high quality tracing and basic ECG interpretation
(specifically how to identify AF).
Computerised and note searches of GP records
Prevalence and incidence data
Computer searches were carried out to identify cases of
probable AF in the 15,000 study patients using a pub-
lished strategy [15]. Searches were tailored towards the
information that is held on computer in each practice. If
practices hold AF registers, or use READ diagnosis coding,
then these were used. In addition, a search was carried out
to identify prescriptions of digoxin, a beta-blocker, a class
1,3 or 4 anti-arrhythmic agent, aspirin or warfarin. This
information was recorded into computerised case report
forms.
Case notes of patients identified as 'known' or 'probable'
AF in any of these computer searches were reviewed for
mention of a diagnosis of AF. AF diagnosis were drawn
from hospital letters stating the existence of the condition
or ECG recordings from the last 5 years.
An additional 5% random sample of case notes of patients
not identified as 'known' or 'probable' AF by computer
searching were reviewed (750 in all) to estimate how
many other patients who are known to have AF were not
identified by the computer searches. If this had revealed a
significant number of extra cases of known AF, then the
sample size for manual searching would have been
increased to allow a precise estimate of the baseline rate of
known AF. Unidentified extra AF cases were not found to
be significant so no additional note search was required.
The same computer searches on both intervention and
control practice patients notes were performed prior to,
and 12 months after, commencement of screening.
Screening clinics
All patients in the systematic screening arm and those
found to have an irregular pulse in the opportunistic
screening arm of the study were invited to attend an ECG
screening clinic. At the clinic the practice nurse explained
the aims of the study and answered any questions about
the study. Written informed consent to participation in
the study was obtained from the patient. The nurse then
recorded baseline information on age, sex, present smok-
ing and alcohol status and past medical history, including
previous diagnosis of AF, and any treatment the patient
may be receiving for AF. Radial pulse rate, and whether
regular or irregular, was noted. A 12 lead ECG, the gold
standard by which other traces were compared, was then
recorded using the Biolog machine, which was also able to
produce a trace corresponding to the single lead thoracic
placement and a rhythm strip of lead II. Finally, the
patient was asked to complete an acceptability
questionnaire.
Discussion
This study will identify the most cost-effective strategy for
identifying atrial fibrillation in patients aged 65 and over.
The policy implications will be dependent on the findings
and one of the strengths of the current study is the utilisa-
tion of modelling techniques to investigate the implica-
tions of different screening strategies and frequency of
screening within different health care environments. The
initial draft of the report has been submitted to the
Department of Health and publication of the results
should be expected later this year (2004).
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